BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Montreal chemists develop fast DNA-based sensor for drug monitoring October 15, 2025 New composite sponge offers rapid and safe control of surgical hemorrhage October 14, 2025 New test could improve future diagnosis and monitoring of IBD January 13, 2026